Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients
Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile
The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.
'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.'
'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.'
In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment.
Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing.
Clinical Development PlansIntellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit clinicaltrials.gov.
About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical ProgramIntellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit clinicaltrials.gov (NCT05120830) for more details. About Lonvo-zBased on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Intellia TherapeuticsIntellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027.
Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.Investors:Brittany ChavesSenior Manager, Investor Relationsbrittany.chaves@intelliatx.com
Media:Matt CrensonTen Bridge Communicationsmcrenson@tenbridgecommunications.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
11 minutes ago
- Bloomberg
Reeves Hails Fiscal Rules as Starmer's Backing Calms Markets
Chancellor of the Exchequer Rachel Reeves stressed her commitment to fiscal discipline in her management of the UK's public finances after reassurances about her position from Prime Minister Keir Starmer led jittery markets to rebound on Thursday. A smiling Reeves was speaking a day after a tearful appearance in Parliament stoked a market selloff amid concerns that the chancellor — who enjoys a reputation for economic discipline — might be about to lose her job following a costly government U-turn on welfare reform. She put her crying down to a 'personal issue,' while Starmer said she'd be in post for 'many years.'
Yahoo
20 minutes ago
- Yahoo
Researchers discover certain gut bacteria can protect you from toxic plastics that increase cancer risks
Could your gut protect you from the toxic impacts of forever chemicals? Forever chemicals, also known as 'PFAS,' are long-lasting, synthetic chemicals that have been used in consumer products around the world since the 1950s. They're found in waterproof clothing, non-stick pans, plastic food packaging, and firefighting foams. Exposure to the chemicals may be tied to negative health impacts, including fertility, developmental delays in children, a weakened immune system, increased cholesterol levels, and a heightened risk of some cancers. There are thousands of forever chemicals that have potentially varying effects and toxicity levels. Now, scientists say they've discovered that some bacteria found in the human gut have the ability to absorb the chemicals — and potentially protect from associated health impacts. 'We found that certain species of human gut bacteria have a remarkably high capacity to soak up PFAS from their environment at a range of concentrations, and store these in clumps inside their cells,' Dr. Kiran Patil, a member of the British University of Cambridge's MRC Toxicology Unit, explained in a statement. 'Due to aggregation of PFAS in these clumps, the bacteria themselves seem protected from the toxic effects.' Patil was the senior author of the research, which was published in the journal Nature Microbiology. To reach these conclusions, the researchers inserted several species of bacteria from the human gut into mice. The study found that nine species of the bacteria gathered the forever chemicals the rodents ate and then pooped out. When exposed to increasing levels of the chemicals, the bacteria worked even harder, consistently removing the same percentage of the toxic chemicals. Within just minutes of exposure, the bacterial species soaked up between a quarter and nearly two-thirds of the forever chemicals. The same effect has not yet been tested in humans, but the researchers said they plan to use their findings to create probiotic dietary supplements that boost the levels of these species in the gut to shield against any PFAS-related health harms. They are also looking at how they could turbo-charge the species' performance. 'The reality is that PFAS are already in the environment and in our bodies, and we need to try and mitigate their impact on our health now,' Dr. Indra Roux, a researcher at the University of Cambridge's MRC Toxicology Unit and a co-author of the study, said. Until then, the researchers say the best thing people can do to protect themselves is to avoid known risks for exposure. Although, even tap water has been contaminated: nearly half of all tap water in America. Under the Trump administration, the Environmental Protection Agency moved to weaken Biden-era standards limiting the pollution of potentially-toxic 'forever chemicals' in U.S. drinking water sources earlier this year. 'PFAS were once considered safe, but it's now clear that they're not,' added fellow researcher Dr. Anna Lindell. 'It's taken a long time for PFAS to become noticed because at low levels they're not acutely toxic. But they're like a slow poison.'
Entrepreneur
2 hours ago
- Entrepreneur
Waste Not, Want Tech
Opinions expressed by Entrepreneur contributors are their own. You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. In the tech world, 'waste' rarely makes the shortlist of blue-chip market opportunities. But for Mikela Druckman, co-founder and CEO of Greyparrot, a clean-tech company using artificial intelligence (AI) to revolutionise waste sorting and recycling, the status quo was a glaring omission. "Depth over breadth has been hugely important for us. From day one, we made a deliberate decision to focus on the waste industry - an under-digitised sector with massive environmental and economic impact." The bet on waste paid off - and fast. By focusing tightly on what she calls "deep domain expertise in waste analytics," Greyparrot turned ignorance into insight and insight into impact. The power of focus Rather than spreading thin, Greyparrot doubled down on a single sector and on one type of technology. "A big early bet was our approach to hardware. While we do deploy hardware to gather data, we made a conscious decision not to build robotic arms or complex recycling plant machinery ourselves." Their team built software that works with existing hardware in recycling plants - from Bollegraaf to Van Dyk - enabling rapid scale without reinventing industrial infrastructure. "That choice set us apart. It allowed us to scale faster, stay agile, and focus on what we do best: building industry-leading AI models, data infrastructure, and integrations that work across any plant setup. We recognised early on that access to large-scale, high-quality data would be one of the most valuable assets we could build - and that's become a core strength." Building with partners Greyparrot's growth model rests on collaboration. By partnering with established players the company expanded from day one - globally. "Greyparrot is an AI and data software specialist, and we partner with the best in the business when it comes to plant builders, robotics, and system integration." These alliances were strategic turbochargers. Together with Bollegraaf and Van Dyk, Greyparrot deployed its systems across 20 countries, analysing tens of billions of waste objects annually. "Today, we're proud to be a global clean tech leader." Reframing waste as gold The world's fastest-growing consumer goods sector was generating almost no intelligence, and Druckman turned that ignorance into opportunity with hard metrics: "In one instance, a single contamination alert from our system saved a European facility £47,000 in reprocessing costs and fines. In another, our AI identified an aluminium sorting issue in minutes - saving £48,000 on a single batch of material." Those case studies became proof. And with packaging under regulatory pressure, Greyparrot's ability to trace material flow upstream - into manufacturing - unlocked a new narrative: "We're helping brands understand the downstream consequences of their packaging design decisions… Insights don't just enhance recycling - they directly inform packaging design, support regulatory compliance, and accelerate progress toward circularity goals." Greyparrot's Deepnest platform takes consumer goods companies into live-feedback mode. Instead of theoretical recyclability, they can now see what happens to packaging post-consumption - data that could prompt rapid design shifts. Eyes wide open When AI meets real-world complexity, blind spots reveal themselves. Greyparrot found wasted money hiding in unexpected places: "I was surprised by the scale of invisible inefficiencies…Over the last year alone, our systems detected and categorised over 40bn waste objects into 111 categories, revealing massive shifts in quality and contamination over the course of a single day." Packing shrink sleeves and resistant materials like Tetra Pak - designed without recycling in mind - became tangible examples of downstream effects. "Take Lucozade bottles - their full plastic shrink sleeve meant that they weren't being recognised by recycling machinery, so they spent £6m to redesign more sustainable products." With real-time data, companies can emerge with 10–20% recovery gains in a single shift. Opportunities in the $3tn waste sector Waste's disruptability is debated, but Druckman points to three major shifts driving this opportunity: 1. Smarter hardware integration, with AI embedded into the sorting process. 2. AI retrofits for legacy plants, offering high ROI without new infrastructure. 3. Emerging data-driven compliance, led through platforms like Deepnest - connecting material flow to brand decisions. "Analysing 15 tonnes of waste typically takes a trained staff member around 375 hours. With AI, it takes six." For entrepreneurs, this suggests embedding your tech, retrofitting old systems, or influencing upstream incentives - while leaving physical assets in place. The reality check Greyparrot's success isn't a fairy tale. The company has survived pandemics, downturns, and hyper-cautious fundraising environments. "One of the biggest lessons that's shaped how we've built Greyparrot is the importance of resilience - not just in the technology, but in the business itself." Steady growth and autonomy in her team proved that momentum didn't rely on a singular figure. "During my second maternity leave, the team not only kept things running - they delivered growth in both headcount and revenue." That's not just good leadership; it's a replicable organisational structure fit for start-ups scaling globally. A circular future Looking ahead, Druckman sees AI as the operating system for recycling plants, but the bigger play lies elsewhere: "AI is laying the foundation for circular decision-making. Data from waste is now flowing upstream to inform how products are designed, tested, and improved - closing the loop between packaging innovation and recyclability." Plants are just the beginning. The next layer is connecting recycling feedback to packaging, design, and supply chains. "Entrepreneurs will play a huge role in scaling this transformation, and that's what we're doing with Deepnest." By rethinking rubbish, Greyparrot shows how innovation can recycle old problems into new possibilities - a truly circular success story.
